最新医学別冊　診断と治療のABC141　うつ病と双極性障害

出版社： 最新医学社
発行日： 2018-12-01
分野： 臨床医学：一般  >  雑誌
ISSN： 03708241
雑誌名：
特集： うつ病と双極性障害
電子書籍版： 2018-12-01
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

5,500 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

2,750 円(税込)

購入する

目次

  • 特集　うつ病と双極性障害

    序
    眼で見るうつ病と双極性障害

    第1章　概念・定義と疫学
    　概念・定義
    　気分障害の疫学（有病率，関連因子，および受診率）

    第2章　病因・病態
    　遺伝
    　うつ病と双極性障害の成因仮説
    　分子イメージングによる気分障害の病態解明
    　うつ病の精神病理―2014年の定義変更を批判する―

    第3章　診断
    　うつ病の診断（鑑別診断を含む）
    　双極性障害の診断（鑑別診断を含む）

    第4章　治療（総論）
    　うつ病の治療
    　双極性障害の治療
    　治療薬剤　
    　　１．抗うつ薬
    　　２．気分安定薬
    　　３．抗精神病薬
    　認知行動療法（CBT）
    　電気けいれん療法の正しい施行法
    　うつ病と双極性障害の心理教育
    　反復経頭蓋磁気刺激療法（rTMS）
    　気分障害のリハビリテーション：リワークプログラムの対象と効果
    　うつ病の経過と予後：GLADS研究から
    　気分障害の経済的側面
    　コラム：SSRIによるアパシー症候群

    第5章　診断・治療(各論)
    　児童・青年期の気分障害における診断と治療
    　高齢者気分障害の臨床的特徴と治療
    　難治性うつ病の診断と治療
    　急速交代型の診断と治療
    　混合状態の診断と治療
    　気分障害と自殺，自傷行為
    　職域の気分障害
    　緩和医療における抑うつ
    　コラム：月経前不快気分障害（PMDD）

    第6章　ガイドライン
    　うつ病の治療ガイドライン
    　双極性障害の治療ガイドライン

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 概念・定義と疫学

P.22 掲載の参考文献
1) 野村総一郎 : 気分障害 : 歴史と概念の変遷. 医学書院, 東京, 2008.
 
2) American Psychiatric Association : Diagnostic and Statistical Manual of Mental Disorders, 5th edition : DSM-5. American Psychiatric Pub, Arlington 2013. (高橋三郎, 他訳 : DSM-5 精神疾患の診断・統計マニュアル (日本精神神経学会監修). 医学書院, 東京, 2014)
 
3) 大前晋 : 双極性障害および関連障害群, 抑うつ障害群, 睡眠-覚醒障害群 : 診断概念の変遷-DSM-III導入まで (Vol. 3). 中山書店, 東京, 2014.
 
4) 樋口輝彦 : 【うつを診る】うつ病の概念とその変遷. [解説/特集] 綜合臨 59 (5) : 1165-1167, 2010.
 
5) 笠原嘉, 他 : うつ状態の臨床的分類に関する研究. 精神誌 77 (10) : 715-735, 1975.
 
6) 白川治 : 【気分障害】双極II型障害 双極スペクトラムへの発展. [解説/特集]. 精神 13 (4) : 286-293, 2008.
 
7) 大森哲郎 : うつ病 (DSM-5) /大うつ病性障害, 単一エピソード : 双極性障害および関連障害群, 抑うつ障害群, 睡眠-覚醒障害群 (神庭重信編). p145-151. 中山書店, 東京, 2014.
 
P.27 掲載の参考文献
1) Ishikawa H, et al : Prevalence, treatment, and the correlates of common mental disorders in the mid 2010's in japan : The results of the world mental health japan 2nd survey. J Affect Disord 241 : 554-562, 2018.
PubMed
2) 川上憲人 : (研究代表者) 精神疾患の有病率等に関する大規模疫学調査研究 : 世界精神保健日本調査セカンド総合研究報告書, 2017.
 
3) Bromet E, et al : Cross-national epidemiology of DSM-IV major depressive episode. BMC Med 9 : 90, 2011.
PubMed
4) Ferrari A J, et al : Global variation in the prevalence and incidence of major depressive disorder : A systematic review of the epidemiological literature. Psychol Med 43 : 471-481, 2013.
PubMed
5) Thornicroft G, et al : Undertreatment of people with major depressive disorder in 21 countries. Br J Psychiatry 210 : 119-124, 2017.
PubMed
6) Wang P S, et al : Use of mental health services for anxiety, mood, and substance disorders in 17 countries in the who world mental health surveys. Lancet 370 : 841-850, 2007.
PubMed
7) Gavin N I, et al : Perinatal depression : A systematic review of prevalence and incidence. Obstet Gynecol 106 : 1071-1083, 2005,
PubMed
8) Mitchell A J, et al : Prevalence and predictors of post-stroke mood disorders : A meta-analysis and meta-regression of depression, anxiety and adjustment disorder. Gen Hosp Psychiatry 47 : 48-60, 2017.
PubMed
9) Roy T, et al : Epidemiology of depression and diabetes : A systematic review. J Affect Disord 142 (Suppl) : S8-21, 2012.
 
10) Li Z, et al : Prevalence of depression in patients with hypertension : A systematic review and meta-analysis. Medicine 94 : e1317, 2015.
PubMed
11) Krebber A M, et al : Prevalence of depression in cancer patients : A meta-analysis of diagnostic interviews and self-report instruments. Psychooncology 23 : 121-130, 2014.
PubMed
12) Vancampfort D, et al : Type 2 diabetes in patients with major depressive disorder A meta-analysis of prevalence estimates and predictors. Depress Anxiety 32 : 763-773, 2015.
PubMed
13) Merikangas K R, et al : Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 68 : 241-251, 2011.
PubMed
14) Kroon J S, et al : Incidence rates and risk factors of bipolar disorder in the general population : A population-based cohort study. Bipolar Disord 15 : 306-313, 2013.
PubMed
15) Laursen T M, et al : A comparison of selected risk factors for unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia from a danish population-based cohort. J Clin Psychiatry 68 : 1673-1681, 2007.
PubMed
16) Marangoni C, et al : The role of environmental exposures as risk factors for bipolar disorder : A systematic review of longitudinal studies. J Affect Disord 193 : 165-174, 2016.
PubMed
17) Mersch P P, et al : Seasonal affective disorder and latitude : A review of the literature. J Affect Disord 53 : 35-48, 1999.
PubMed
18) Whiteford H A, et al : Global burden of disease attributable to mental and substance use disorders : Findings from the global burden of disease study 2010. Lancet 382 : 1575-1586, 2013.
PubMed
19) Vos T, et al : Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013 : A systematic analysis for the global burden of disease study 2013. Lancet 386 : 743-800, 2015.
PubMed

第2章 病因・病態

P.33 掲載の参考文献
1) 西澤由貴, 他 : うつ病って遺伝するのですか? 原因となる遺伝子はわかっているのですか?, Depression Frontier 2 うつ病臨床のこんな疑問に答える-脳科学からのアプローチ-. 医薬ジャーナル社, 東京, 2016.
 
2) 町田康博, 他 : 統合失調症と双極性障害の遺伝子 (特集 統合失調症と双極性障害あるいは自閉症スペクトラムの関連性). 精神 32 (3) : 243-246, 2018.
 
3) Mendlewicz J, et al : Morbidity risk and genetic transmission in manic-depressive illness. Am J Hum Genet 26 (6) : 692-701, 1974.
PubMed
4) Wender P H, et al : Psychiatric disorders in the biological and adoptive families of adopted individuals with affective disorders. Arch Gen Psychiatry 43 (10) : 923-929, 1986.
PubMed
5) Tsuang M T, et al : Morbidity risks of schizophrenia and affective disorders among first degree relatives of patients with schizophrenia, mania depression and surgical conditions. Br J Psychiatry 137 : 497-504, 1980.
PubMed
6) Bertelsen A, et al : A Danish twin study of manicdepressive disorders. Br J Psychiatry 130 : 330-351, 1977.
PubMed
7) Segurado R, et al : Genome scan meta-analysis of schizophrenia and bipolar disorder, part III : Bipolar disorder. Am J Hum Genet 73 (1) : 49-62, 2003.
PubMed
8) Kato T : Molecular genetics of bipolar disorder and depression. Psychiatry Clin Neurosci 61 (1) : 3-19, 2007.
PubMed
9) Johnson E C, et al : No Evidence That Schizophrenia Candidate Genes Are More Associated With Schizophrenia Than Noncandidate Genes. Biol Psychiatry 82 (10) : 702-708, 2017.
PubMed
10) Wellcome Trust Case Control Consortium : Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447 (7145) : 661-678, 2007.
 
11) Ha N T, et al : Coverage and efficiency in current SNP chips. Eur J Hum Genet 22 (9) : 1124-1130, 2014.
PubMed
12) Ferreira M A, et al : Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet 40 (9) : 1056-1058, 2008.
PubMed
13) 丸山惣一郎, 他 : 激越型うつ病にmirtazapineが奏効した3例-薬理学的疾患分類の可能性を鑑みて. 精神医 56 (4) : 285--291, 2014.
 
14) Wray N R, et al : Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet 50 (5) : 668-681, 2018.
PubMed
15) Cross-Disorder Group of the Psychiatric Genomics Consortium, et al : Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet 45 (9) : 984-994, 2013.
 
16) Ikeda M, et al : A genome-wide association study identifies two novel susceptibility loci and trans population polygenicity associated with bipolar disorder, Mol Psychiatry 23 (3) : 639-647, 2018.
 
P.45 掲載の参考文献
1) American Psychiatric Association : The dexamethasone suppression test : an overview of its current status in psychiatry. The APA Task Force on Laboratory Tests in Psychiatry. Am J Psychiatry 144 : 1253-1262, 1987.
 
2) Kunugi H, et al : Assessment of the dexamethasone/CRH test as a state-dependent marker for hypothalamic-pituitary-adrenal (HPA) axis abnormalities in major depressive episode : a Multicenter Study. Neuropsychopharmacology 31 : 212-220, 2006.
PubMed
3) 功刀浩, 他 : うつ病のバイオマーカーと亜型-特に視床下部-下垂体-副腎系機能との関連について-. 臨精医 42 (8) : 991-998, 2013.
Medical*Online
4) Yoon H S, et al : Relationships of Cerebrospinal Fluid Monoamine Metabolite Levels With Clinical Variables in Major Depressive Disorder. J Clin Psychiatry 78 : e947-e956, 2017.
PubMed
5) Ogawa S, et al : Cerebrospinal fluid monoamine metabolite concentrations in depressive disorder : A meta-analysis of historic evidence. J Psychiatr Res 105 : 137-146, 2018.
PubMed
6) Duman R S, et al : A neurotrophic model for stress-related mood disorders. Biol Psychiatry 59 : 1116-1127, 2006.
PubMed
7) Numakawa T, et al : Glucocorticoid receptor interaction with TrkB promotes BDNF-triggered PLC-gamma signaling for glutamate release via a glutamate transporter. Proc Natl Acad Sci USA 106 : 647-652, 2009.
 
8) 功刀浩 : 精神疾患の脳科学講義. 金剛出版, 東京, 2012.
 
9) Dowlati Y, et al : A meta-analysis of cytokines in major depression. Biol Psychiatry 67 : 446-457, 2010.
PubMed
10) Ogawa S, et al : Plasma L-tryptophan concentration in major depressive disorder : new data and meta-analysis. J Clin Psychiatry 75 : e906-915, 2014.
PubMed
11) Sasayama D, et al : Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. J Psychiatr Res 47 : 401-406, 2013.
PubMed
12) Wium-Andersen M K, et al : Association between elevated plasma fibrinogen and psychological distress, and depression in 73,367 individuals from the general population. Mol Psychiatry 18 (8) : 854-855, 2013.
PubMed
13) Hattori K, et al : Increased cerebrospinal fluid fibrinogen in major depressive disorder. Sci Rep 5 : 11412, 2015.
PubMed
14) Craddock N, et al : Genetics of bipolar disorder. J Med Genet 36 : 585-594, 1999.
PubMed
15) Craddock N, et al : Genetics of bipolar disorder. Lancet 381 : 1654-1662, 2013.
PubMed
16) Ikeda M, et al : A genome-wide association study identifies two novel susceptibility loci and trans population polygenicity associated with bipolar disorder. Mol Psychiatry 23 (3) : 639-647, 2018.
 
17) Harwood A J : Lithium and bipolar mood disorder : the inositol-depletion hypothesis revisited. Mol Psychiatry 10 : 117-126, 2005.
PubMed
18) Beaulieu J M, et al : Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A 101 (14) : 5099-5104, 2004.
PubMed
19) Li X, et al : Regulation of glycogen synthase kinase-3 during bipolar mania treatment Bipolar Disord 12 (7) : 741-752, 2010.
PubMed
20) Jope R S : Glycogen synthase kinase-3 in the etiology and treatment of mood disorders. Front Mol Neurosci 4 : 16, 2011.
PubMed
21) Kato T, et al : Mitochondrial dysfunction in bipolar disorder. Bipolar Disord 2 : 180-190, 2000.
PubMed
22) Kuang H, et al : Lactate in bipolar disorder : A systematic review and meta-analysis. Psychiatry Clin Neurosci 2018 (in press).
 
P.51 掲載の参考文献
1) Shioe K, et al : No association between genotype of the promotor region of serotonin transporter gene and serotonin transporter binding in human brain measured by PET. Synapse 48 (4) : 184-188, 2003.
PubMed
2) Ichimiya T, et al : Serotonin transporter binding in patients with mood disorders : A PET study with [11C] (+) McN5652. Biol Psychiatry 51 (9) : 715-722, 2002.
PubMed
3) Meyer J H, et al : Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses : an [11C] DASB positron emission tomography study. Am J Psychiatry 161 (5) : 826-835, 2004.
PubMed
4) Goulding V, et al : Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression : a [11C] DASB PET imaging study. Am J Psychiatry 158 (11) : 1843-1849, 2001.
 
5) Drevets W C, et al : PET imaging of serotonin-1A receptor binding in depression. Biol Psychiatry 46 (10) : 1375-1387, 1999.
 
6) Sargent P A, et al : Brain serotonin 1A receptor binding measured by positron emission tomography with [11C] WAY-100635 : effects of depression and antidepressant treatment. Arch Gen Psychiatry 57 (2) : 174-180, 2000.
 
7) Bhangwager Z, et al : Persistent reduction in brain serotonin 1A receptor binding in recovered depressed men measured by positron emission tomography with [11C] WAY-100635. Mol Psychiatry 9 (4) : 386-392, 2004.
PubMed
8) Saijo T, et al : Effect of electroconvulsive therapy on 5-HT1A receptor binding in patients with depression : a PET study with [11C] WAY 100635. Int J Neuropsychopharmacol 13 (6) : 785-791, 2010.
PubMed
9) Biver F, et al : Serotonin 5-HT2 receptor imaging in major depression : focal changes in orbito-insular cortex. Br J Psychiatry 171 (5) : 444-448, 1997.
PubMed
10) Attar-Levy D, et al : The cortical serotonin 2 receptors studied with positron-emission tomography and [18F] -setoperone during depressive illness and antidepressant treatment with clomipramine. Biol Psychoatry 45 (2) : 180-186, 1999.
 
11) Meyer J H, et al : Prefrontal cortex 5-HT2 receptors in depressiorr an [18F] setoperone PET imaging study. Am J Psychiatry 156 (7) : 1029-1034, 1999.
PubMed
12) Meyer J H, et al : The effect of paroxetine on 5-HT2A receptors in depression : an [18F] setoperone PET imaging study. Am J Psychiatry 158 (1) : 78-85, 2001.
PubMed
13) Okubo Y, et al : Possible role of dopamine D1 receptors in schizophrenia. Mol Psychiatry 2 (4) : 291-292, 1997.
PubMed
14) Okubo Y, et al : Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 385 (6617) : 634-636, 1997.
PubMed
15) Fujimura Y, et al : Quantitative analyses of 18F-FEDAA1106 binding to peripheral benzodiazepine receptors in living human brain. J Nucl Med 47 (1) : 43-50, 2006.
 
16) Richards E M, et al : PET radioligand binding to translocator protein (TSPO) is increased in unmedicated depressed subjects. EJNMMI Res 8 (1) : 57, 2018.
PubMed
17) Setiawan E, et al : Association of translocator protein total distribution volume with duration of untreated major depressive disorder : a cross-sectional study. Lancet Psychiatry 5 (4) : 339-347, 2018.
PubMed
18) Li H, et al : Translocator protein (18kDa TSPO) binding, a marker of microglia is reduced in major depression during cognitive-behavioral therapy. Prog Neuropsychopharmacol Biol Psychiatry 83 : 1-7, 2018.
 
P.59 掲載の参考文献
1) American Psychiatric Association : Diagnostic and Statistical Manual of Mental Disorders ; Fifth Edition : DSM-5TM. American Psychiatric Association, Arlington, 2013. (高橋三郎, 他訳 : DSM-5 精神疾患の診断・統計マニュアル. 医学書院, 東京, 2014.)
 
2) Hamilton M : Mood disorders : clinical features. In : Comprehensive Textbook of Psychiatry 5th ed (Kaplan H I, et al, eds). p892-913. Williams & Wilkins, Baltimore, 1989.
 
3) 大前晋 : 個人が悩みをかかえきれなくなったとき, 社会的に求められる機能を果たせなくなったとき, 精神科医療は何ができるのか-うつ病概念と, それが指し示す範囲すなわちスペクトラム-. 精神医学の基盤 [3] 特集 精神医学におけるスペクトラムの思想 (村井俊哉, 他編). p127-139. 学樹書院, 東京, 2016.
 
4) 大前晋 : 「大うつ病性障害」ができるまで-DSM-III 以前の「うつ病」 (内因性抑うつ) と現代の「うつ病」 (大うつ病性障害) の関係-. 精神経誌 114 : 886-905, 2012.
 
5) 笠原嘉, 木村敏 : うつ状態の臨床的分類に関する研究. 精神経誌 77 : 715-735, 1975. (笠原嘉 : うつ病臨床のエッセンス 新装版. p15-70. みすず書房, 東京, 2015.)
 
6) 平沢一 : うつ病の臨床精神医学的研究の現況 (1945-1958). 精神医 1 : 211-223, 1959.
 
7) 内村祐之 : 鬱病の診断と治療, 日醫新報 1188 : 3-5, 10, 1946.
 
8) 平澤一 : 軽症うつ病の臨床と予後. 医学書院, 東京, 1966.
 
9) Weitbrecht H J : Zur Typologie depressiver Psychosen. Fortschr Neurol Psychiatr Grenzgeb 20 : 247-269, 1952.
 
10) 大前晋 : うつ病の文化論的理解-ニッポンの「うつ病」1959-1978-. 精神科 32 : 13-18, 2018.
 
11) 玉田有 : 執着性格論 (下田光造) の構成過程に関する考察-森田正馬による精神病質論と比較して-. 精神経誌 120 : 11-24, 2018.
 
12) Tellenbach H : Melancholie : zur Problemgeschichte-Typologie Pathogenese und Klinik. Springer, Berlin, 1961. (第4版) 木村敏訳 : メランコリー〔改訂増補版〕. みすず書房, 東京, 1985.
 
13) 大前晋 : Tellenbachのメランコリー論再説-その構築過程と理論的意義-. 精神経誌 115 : 711-728, 2013.
 
14) Kielholz P : Diagnostik und Therapie der depressiven Zustandbilder. Schweiz Med Wochenschr 87 : 87-90, 107-110, 1957.
 
15) 立山萬里訳. VI. イミプラミン (スイス, 1957年). 精神病治療薬の原点-国外重要文献全訳集- (保崎秀夫監訳, 八木剛平編・解). p70-83. 金剛出版, 東京, 1987.
 
15) Kuhn R : Uber die Behandlung depressiver Zustande mit einen Iminobenzylderivat (G22355). Schweiz Med Wochenschr 87 : 1135-1140, 1957.
 
16) 笠原嘉 : うつ病 (病相期) の小精神療法. 季刊精神療法 4 : 118-124, 1978.
 
17) 笠原嘉 : うつ病の管理と社会復帰. 内科セミナー PN6 うつ病 (織田敏次, 他編). p241-251. 永井書店, 東京, 1982. (笠原嘉. うつ病臨床のエッセンス 新装版. p151-167. みすず書房, 東京, 2015. (「うつ病の治療と社会復帰」に改題))
 
18) 大熊輝夫 : 現代臨床精神医学 改訂第2版. 金原出版, 東京, 1983.
 
19) 笠原嘉 : 職場に今も多い内因性の軽症うつ病-「まじめ人間」「中年」「自殺観念」の三徴候に注目します-. IMH産業精保健研 8 : 3-18, 2017.
 
20) 笠原嘉 : 「復職」サポートについて我々にできること, できないこと-不安神経症と軽症うつ病を中心に-. IMH産業精保健研 6 : 3-17, 2015.
 

第3章 診断

P.66 掲載の参考文献
1) 大坪天平 : 日常診療におけるうつ病 (2) -総合病院から本物のうつ病を再考する-. うつ病診療の論理と倫理. p123-131, 学樹書院, 東京, 2015.
 
2) American Psychiatric Association : Diagnostic and statistical manual of mental disorders, 5th edition : DSM-5. American Psychiatric Pub, Arlington, 2013. (高橋三郎, 他訳 : DSM-5 精神疾患の診断・統計マニュアル (日本精神神経学会監修). p160-167. 医学書院, 東京, 2014)
 
3) 日本うつ病学会気分障害の治療ガイドライン作成委員会編 : 日本うつ病学会治療ガイドライン II. うつ病 (DSM-5) /大うつ病性障害 2016. 2016.
 
4) 原田憲一 : 精神症状の把握と理解. p61-83, 中山書店, 東京, 2008.
 
5) 野村総一郎 : 精神科臨床エキスパート. 抑うつの鑑別を極める. p2-22, 医学書院, 東京, 2014.
 
6) 古茶大樹 : 臨床精神病理学的視点から見たうつ病の診断学. うつ病診療の論理と倫理. p78-87, 学樹書院, 東京, 2015.
 
7) Wakefield J C, et al : When does depression become a disorder? Using recurrence rates to evaluate the validity of proposed changes in major depression diagnostic thresholds. World Psychiatry 12 : 44-52, 2013.
PubMed
8) 玉田有, 他 : 慢性うつ病の臨床におけるdemoralization概念の重要性. 臨精医 46 : 607-612, 2017.
Medical*Online
9) Klein D F : Endogenomorphic depression. A conceptual and terminological revision. Arch Gen Psychiatry 31 : 447-454, 1974.
PubMed
10) Ghaemi S N, et al : Bipolar spectrum disorder : a pilot study. Psychopathology 37 : 222-226, 2004.
PubMed
11) Radloft L S : The CES-D Scale : a self report depression scale for research in general population. App Psychol Meas 1 : 385-401, 1997.
 
12) 大坪天平 : 精神疾患簡易構造化面接法 (M. I. N. I., M. I. N. I. KIDなど). 臨精医 44 増刊号 : 16-21, 2015.
 
P.75 掲載の参考文献
1) 日本うつ病学会 双極性障害委員会 : 双極性障害 (躁うつ病) とつきあうために. 2018.
 
2) ベンジャミン J サドック, 他 : 第8章 気分障害. カプラン臨床精神医学テキスト DSM-5 診断基準の臨床への展開 第3版 (井上令一監修). メディカル・サイエンス・インターナショナル, 東京, 2016.
 
3) 秋山剛編 : 「はたらく」を支える! 職場×双極性障害. 南山堂, 東京, 2018.
 
4) American Psychiatric Association : DSM-5 精神疾患の診断・統計マニュアル (高橋三郎, 他監訳). 医学書院, 東京, 2014.
 
5) Hirschfeld R M : Differential diagnosis of bipolar disorder and major depressive disorder. J Affect Disord 169 : S1, S12-S16, 2014.
 
6) 内海健 : ヒポマニーの精神病理-4つのスペクトラムによる変奏. 精神医 60 (7) : 707-718, 2018.
 
7) 武島稔 : 双極性障害, bipolarityのあるうつ病の可能性. 精神 30 (6) : 468-475, 2017.
 
8) Inoue T, et al : Prevalence and predictors of bipolar disorders in patients with a major depressive episode : The Japanese epidemiological trial with latest measure of bipolar disorder (JET-LMBP). J Affect Disord 174 : 535-541, 2015.
 
9) マルク・マソン : 双極性障害 (阿部又一郎, 他監訳), 白水社文庫クセジュ, 東京, 2018.
 
10) 山内俊雄, 他編 : 精神・心理機能評価ハンドブック. 中山書店, 東京, 2015.
 
11) Hirschfeld R M, et al : Development and validation of a screening instrument for bipolar spectrum disorder : the Mood Disorder Questionnaire. Am J Psychiatry 157 (11) : 1873-1875, 2000.
PubMed
12) 田中輝明, 他 : 単極性うつ病か? 双極性うつ病か? 自己記入式評価スケールの有用性に関する検討. Bipolar Disorder 5 : 21-27, 2007.
 
13) Angst J, et al : The HCL-32 : towards a self-assessment tool for hypomanic symptoms in outpatients. J Affect Disord 88 : 217-233, 2005.
PubMed
14) 阿部又一郎, 他 : Hypomania Check List改定第1版 (HCL-32 R1) の紹介と日本語版作成の試み. 精神 20 (5) : 554-566, 2012.
 
15) 阿部又一郎, 他 : 軽躁自記式評価尺度 (HCL-33) 日本語版試案を作成する. 精神 24 (2) : 271-276, 2014.
 
16) Feng Y, et al : The 33-item Hypomania Checklist (HCL-33) : A new self-completed screening instrument for bipolar disorder. J Affect Disord 190 : 214-220, 2016,
PubMed
17) 川上憲人 : 職域におけるうつ病の早期発見の新しい技術の開発と普及, 2. 職場用双極性障害スクリーニング尺度の作成. 平成21年度厚生労働科学研究費補助金こころの健康科学研究事業「リワークプログラムを中心とするうつ病の早期発見から職場復帰に至る包括的治療に関する研究」(研究代表者秋山剛), 2009.
 
18) Imamura K, et al : Development of screening inventories for bipolar disorder at workplace : a diagnostic accuracy study. J Affect Disord 178 : 32-38, 2015.
PubMed
19) Akiskal H S, et al : TEMPS-A : progress towards validation of a self-rated clinical version of the Temperament Evaluation of the Memphis, Pisa, Paris, and San Diego Autoquestionnaire. J Affect Disord 85 (1-2) : 3-16, 2005.
 
20) 秋山剛, 他 : 循環気質とメランコリー気質 : 気分障害の性格特徴に関する実証研究. 精神誌 105 : 533-543, 2003.
 
21) Takeshima M, et al : Comparative analysis of affective temperament in patients with difficult-to-treat and easy-to-treat major depression and bipolar disorder : Possible application in clinical settings. Compr Psychiatry 66 : 71-78, 2016.
PubMed
22) 田中輝明 : 双極性障害における診断の変遷と薬物療法の進歩. 臨精薬理 21 : 313-319, 2018.
 
23) 大前晋 : 双極性障害を「双極性」障害と認識するのはなぜですか? そして双極性「障害」はモノですか? それともコトですか? 臨精医 46 (6) : 749-758, 2017.
Medical*Online
24) Kato T, et al : Survey on attitudes towards renaming bipolar disorder in Japanese. Psychiatry Clin Neurosci 72 (1) : 45, 2018.
PubMed
25) 井上猛, 他 : 特集 双極II型をめぐる諸問題. 精神医 60 (7) : 699-772, 2018.
 
26) 神庭重信, 他 : 気分障害の臨床を語る : 変わること, 変わらないこと. 創元社, 大阪, 2018.
 

第4章 治療 ( 総論 )

P.84 掲載の参考文献
1) Rush A J, et al : Acute and longer-term out-comes in depressed outpatients requiring one or several treatment steps : a STAR*D report. Am J Psychiatry 163 : 1905-1917, 2006.
 
2) Kupfer D J, et al : Lessons to be learned from long-term treatment of affective disorders : potential utility in panic disorder. J Clin Psychiatry 52 (suppl. 2) : 12-16, 1991.
 
3) National Institute for Health and Clinical Excellence : The treatment and management of depression in adults <www.nice.org/uk/CG90>
 
4) 八木剛 : 脆弱性モデルからレジリアンスモデルへ精神疾患におけるレジリアンス生物学的研究を中心に. 精神誌 110 : 770-775, 2008.
 
5) Richards D, et al : Cost and Outcome of Behavioural Activation versus Cognitive Behavioural Therapy for Depression (COBRA) : a randomised, controlled, non-inferiority trial. Lancet 388 : 871-880, 2016.
 
6) 日本うつ病学会 : 気分障害の治療ガイドライン作成委員会 : 日本うつ病学会治療ガイドライン II. うつ病 (DSM-5) /大うつ病性障害 2016. 日本うつ病学会. 2016.
 
7) Karasu T B : Toward a clinical model of psychotherapy for depression : 2 An integrative and selective treatment approach. Am J Psychiatry 147 : 274, 1990.
 
8) Corney R H : Marital problems and treatment outcome in depressed women. Compr Psychiatry 151 : 652-659, 1987.
 
9) Cwortherr J H : The relationship between depression and marital maladustment a descriptive study. J Nerv Ment Dis 173 : 227-231, 1985.
 
10) Weissman M, et al : The Depression women : A study of her relationships. University of Chicago Press. Chicago, 1970.
 
11) 眞鍋貴子, 他 : うつ病再発予防講習会 (Depression prevention program : DPP) の臨床有用性, 慈恵医大誌 131 (4) : 111--119, 2016.
 
12) 福迫博, 他 : 磁気刺激の抗うつ作用. 脳の科学 21 : 193-199, 1999.
 
13) 公益社団法人 日本精神神経学会 新医療機器使用要件等基準策定事業rTMS適正使用指針作成ワーキンググループ : 平成29年度 新医療機器使用要件等基準策定事業 (反復経頭蓋磁気刺激装置) 事業報告書. 2018.
 
14) Eliabeth H B, et al : "The role of primary care physician in patient's adherence to antidepressant therapy." Med Care 33 : 67-74, 1995.
 
15) Kupfer D J, et al : Five-year outcome for maintenance therapy in recurrent depression. Arc Gen Psychiatry 49 : 769-773, 1992.
 
16) 辻敬一郎, 他 : 抗うつ薬, 気分安定薬の離脱に伴う問題と安全な減量中止の方法. 臨精薬理 20 : 1033-1042, 2017.
 
P.94 掲載の参考文献
1) 日本うつ病学会治療ガイドライン I. 双極性障害 2017. <http://www.secretariat.ne.jp/jsmd/mood_disorder/img/171130.pdf>
 
2) 加藤忠史 : 双極性障害 第2版-病態の理解から治療戦略まで-. 医学書院, 東京, 2011.
 
3) 大森哲郎編 : 専門医のための精神科臨床リュミエール 6「双極性障害」. 中山書店, 東京, 2008.
 
4) Goodwin F K, et al : Manic-Depressive Illness : Bipolar Disorders and Recurrent Depression. Oxford University Press, New York, 2007.
 
5) Akiskal H S, et al : Bipolar Psychopharmacotherapy : Caring for the patient, 2nd Ed. Wiley-Blackwell, U S A, 2011.
 
6) Yatham L N, et al : Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 20 (2) : 97-120, 2018.
 
P.102 掲載の参考文献
1) 加藤正樹 : 治療抵抗性抗うつに対し外来診療でできる薬物療法. 精神誌 120 : 391-400, 2018.
 
2) Bauer M, et al : World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1 : update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry 14 : 334-385, 2013.
PubMed
3) Souery D, et al : Clinical factors associated with treatment resistance in major depressive disorder : results from a European multicenter study. J Clin Psychiatry 68 : 1062-1070, 2007.
PubMed
4) 精神科薬物療法研修特別委員会, 日本精神科薬物療法グッドプラクティス-ワンランク上の処方をめざして-. 2015.
 
P.109 掲載の参考文献
1) Keller M B, et al : A five-year prospective follow-up. J Nerv Ment Dis 181 (4) : 238-245, 1993.
PubMed
2) Allen M H, et al : Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. Am J Psychiatry 163 (2) : 272-275, 2006.
PubMed
3) Katayama Y, et al : Therapeutic window of lamotrigine for mood disorders : a naturalistic retrospective study. Pharmacopsychiatry 47 (3) : 111-114, 2014.
PubMed
4) Kamei K, et al : A Predictive model of plasma lamotrigine levels. Pharmacopsychiatry 49 (5) : 182-185, 2016.
PubMed
5) Yildiz A, et al : A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania. Psychol Med 45 (2) : 299-317, 2015.
 
6) Glue P, et al : Comparative efficacy and acceptability of combined antipsychotics and mood stabilizers versus individual drug classes for acute mania : Network meta-analysis. Aust N Z J Psychiatry 49 (12) : 1215-1220, 2015.
PubMed
7) McGirr A, et al : Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression : a systematic review and meta-analysis of randomised placebo-controlled trials. Lancet Psychiatry 3 (12) : 1138-1146, 2016.
 
8) Amsterdam J D, et al : Short-term venlafaxine v. lithium monotherapy for bipolar type II major depressive episodes : effectiveness and mood conversion rate. Br J Psychiatry 208 (4) : 359-365, 2016.
PubMed
9) Lorenzo-Luaces L, et al : Effects of venlafaxine versus lithium monotherapy on quality of life in bipolar II major depressive disorder : Findings from a double-blind randomized controlled trial. Psychiatry Res 259 : 455-459, 2018.
PubMed
10) Solmi M, et al : Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression : a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. CNS Spectr 21 (5) : 403-418, 2016.
PubMed
11) Joas E, et al : Pharmacological treatment and risk of psychiatric hospital admission in bipolar disorder. Br J Psychiatry 210 (3) : 197-202, 2017.
PubMed
12) Goodwin G M, et al : A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 65 (3) : 432-441, 2004.
PubMed
13) Terao T, et al : Preventive Effects of Lamotrigine in Bipolar II Versus Bipolar I Disorder. J Clin Psychiatry 78 (8) : e1000-e1005, 2017.
PubMed
14) Lahteenvuo M, et al : Real-world Effectiveness of Pharmacologic Treatments for the Prevention of Rehospitalization in a Finnish Nationwide Cohort of Patients With Bipolar Disorder. JAMA Psychiatry 75 (4) : 347-355, 2018.
 
15) Bauer M S, et al : A population-based study of the comparative effectiveness of second-generation antipsychotics vs older antimanic agents in bipolar disorder. Bipolar Disord 18 (6) : 481-489, 2016.
PubMed
16) Hochman E, et al : Antipsychotic adjunctive therapy to mood stabilizers and 1-year rehospitalization rates in bipolar disorder : A cohort study. Bipolar Disord 18 (8) : 684-691, 2016.
PubMed
17) Song J, et al : Suicidal Behavior During Lithium and Valproate Treatment : A Within-Individual 8-Year Prospective Study of 50,000 Patients With Bipolar Disorder. Am J Psychiatry 174 (8) : 795-802, 2017.
PubMed
18) Terao T, et al : Mixed Features in Bipolar I Disorder and the Effect of Lithium on Suicide. Am J Psychiatry 175 (1) : 80, 2018.
PubMed
19) Kanehisa M, et al : Serum lithium levels and suicide attempts : a case-controlled comparison in lithium therapy-naive individuals. Psychopharmacology (Berl) 234 (22) : 3335-3342, 2017.
PubMed
20) Terao T, et al : Lithium and dementia : a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 30 (6) : 1125-1128, 2006.
PubMed
21) Kessing L V, et al : Does lithium protect against dementia? Bipolar Disord 12 (1) : 87-94, 2010.
PubMed
22) Kessing L V, et al : Lithium treatment and risk of dementia0 Arch Gen Psychiatry 65 (11) : 1331-1335, 2008.
 
23) Gerhard T, et al : Lithium treatment and risk for dementia in adults with bipolar disorder : population-based cohort study. Br J Psychiatry 207 (1) : 46-51, 2015.
PubMed
24) Terao T : Aggression, suicide, and lithium treatment. Am J Psychiatry 165 (10) : 1356-1357, 2008.
PubMed
P.119 掲載の参考文献
1) Grande I, et al : Bipolar disorder. Lancet 387 (10027) : 1561-1572, 2016.
PubMed
2) Judd L L, et al : The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 59 (6) : 530-537, 2002.
 
3) Pompili M, et al : Epidemiology of suicide in bipolar disorders : a systematic review of the literature. Bipolar Disord 15 (5) : 457-490, 2013.
PubMed
4) Schaffer A, et al : International Society for Bipolar Disorders Task Force on Suicide : meta-analyses and meta-regression of correlates of suicide attempts and suicide deaths in bipolar disorder. Bipolar Disord 17 (1) : 1-16, 2015.
PubMed
5) Yatham L N, et al : Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 20 (2) : 97-170, 2018.
 
6) Yildiz A, et al : A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania. Psychol Med 45 (2) : 299-317, 2015.
 
7) Taylor D M, et al : Comparative efficacy and acceptability of drug treatments for bipolar depression : a multiple-treatments meta-analysis. Acta psychiatrica Scandinavica 130 (6) : 452-469, 2014.
PubMed
8) Miura T, et al : Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder : a systematic review and network meta-analysis. Lancet Psychiatry 1 (5) : 351-359, 2014.
PubMed
P.128 掲載の参考文献
1) Beck A T, et al : Cognitive Therapy for Depression. Guilford Press, New York, 1976. (アーロン・T・ベック, 他 : うつ病の認知療法 <新版>, 岩崎学術出版社, 東京, 2007)
 
2) ラム D H, 他 : 双極性障害の認知行動療法 (北川信樹, 他監訳). 岩崎学術出版社, 東京, 2012.
 
3) 坂野雄二 : 認知行動療法の基礎. 金剛出版, 東京, 2011.
 
4) National Institute for health and Clinical Excellence : Depression : The treatment and management of depression in adults. British Psychological Society and Gaskell, 2009.
 
5) 日本うつ病学会気分障害の治療ガイドライン作成委員会 : 日本うつ病学会治療ガイドライン II. うつ病 (DSM-5) /大うつ病性障害. 2016. <http://www.secretariat.ne.jp/jsmd/mood_disorder/img/160731.pdf>
 
6) 日本うつ病学会気分障害の治療ガイドライン作成委員会 : 日本うつ病学会治療ガイドライン I. 双極性障害. 2017. <http://www.secretariat.ne.jp/jsmd/mood_disorder/img/180125.pdf>
 
7) Beck J S : Cognitive therapy : basics and beyond. Gulford Press, New York, 1995 (ジュディス・S・ベック (伊藤絵美, 他訳) : 認知療法実践ガイド基礎から応用まで. 星和書店, 東京, 2004)
 
8) 坂野雄二 : 認知行動療法の基本的発想を学ぶ. こころの科学 121 : 26-30, 2005.
 
9) 飯倉康郎, 他 : 行動療法. 臨床精神医学講座, 第15巻 (松下正明編), p251-272. 中山書店, 東京, 1999.
 
10) 平成21年度厚生労働科学研究費補助金こころの健康科学研究事業「精神療法の実施方法と有効性に関する研究」 : うつ病の認知療法・認知行動療法マニュアル. 2010. <https://www.mhlw.go.jp/bunya/shougaihoken/kokoro/dl/01.pdf>
 
11) 鈴木伸一, 他 : うつ病の集団認知行動療法 実践マニュアル-再発予防や復職支援に向けて-. 日本評論社, 東京, 2011.
 
P.136 掲載の参考文献
1) Fink M : Electroconvulsive Therapy : A Guide for Professionals and Their Patients. Oxford University Press, 2009 (鈴木一正, 他訳 : 電気けいれん療法 医師と患者のためのガイド. 新興医学出版社, 東京, 2010).
 
2) 上田諭 : 電気けいれん療法は必須の精神科治療である-電気ショック批判にこたえる. 精神科臨床はどこへいく (こころの科学増刊) (井原裕編), p52-58. 日本評論社, 東京, 2011.
 
3) 上田諭, 他 : ECTにおける有効な発作誘発のaugmentation. 総病精医 22 : 153-161, 2010.
 
4) Ueda S, et al : Successful switching from sine-wave to pulse-wave with oral theophylline the night before ECT for depression. Psychiatry Clin Neurosci 65 : 604-605, 2011.
 
5) 本橋伸高, 他 : 電気けいれん療法 (ECT) 推奨事項改訂版. 精神誌 115 : 586-600, 2013.
 
6) Mankad M V, et al : Clinical Manual of Electroconvulsive Therapy. American Psychiatric Publishing Inc, Washington DC, 2010 (本橋伸高, 他監訳, 鈴木一正, 他訳 : パルス波ECTハンドブック. 医学書院, 東京, 2012).
 
7) American Psychiatric Association Committee on Electroconvulsive Therapy : Practice of electroconvulsive therapy : Recommendation for treatment, training, and privileging. 2nd edition. A Task Force Report of the American Psychiatric Association. American Psychiatric Association, Washington DC, 2001 (日本精神神経学会電気けいれん療法の手技と適応基準の検討小委員会監訳 : 米国精神医学会タスクフォースレポートECT実践ガイド. 医学書院, 東京, 2002).
 
8) 上田諭 : ECTにおける発作評価と「治療閾値」の重要性-米国のVisiting Fellowshipに参加して. 精神医 49 : 1135-1141, 2007.
 
9) Azuma H, et al : Postictal suppression correlates with therapeutic efficacy for depression in bilateral sine and pulse wave electroconvulsive therapy. Psychiatry Clin Neurosci 61 : 168-173, 2007.
PubMed
10) 澤村岳人, 他 : パルス波治療器を使用したmECTにより遷延性けいれんを生じた一例. 総病精医 22 (Suppl) : S181, 2010.
 
11) 岩本崇志, 他 : 修正型電気けいれん療法 (mECT) 施行時のthiamylal sodium投与量についての検討. 精神医 52 : 873-881, 2010.
 
12) Takekita Y, et al : Remifentanil in electroconvulsive therapy : a systematic review and meta-analysis of randomized controlled trials. Eur Arch Psychiatry Clin Neurosci 266 : 703-717, 2016.
PubMed
13) 澤山恵波, 他 : 「電気けいれん療法 (ECT) 推奨事項改訂版」に則り標準化と可視化を追求したパス改訂. 精神科治療 31 : 1529-1535, 2016.
 
14) 宮吉孝明, 他 : Flumazenilの麻酔前投与を行いbenzodiazepineとECTの併用療法が著効した緊張病症候群の1症例. 臨精医 38 : 1397-1403, 2009.
Medical*Online
15) Suzuki K, et al : Panic attack associated with flumazenil at electroconvulsive therapy session. J ECT 25 : 145, 2009.
 
16) 上田諭, 他 : 電気けいれん療法 (ECT) は倫理的な治療か-「精神医学論争-電気ショックをめぐる攻防-」 (吉村, 2007) をめぐって (座談会). 精神科治療 31 : 1611-1618, 2016.
 
17) Swartz C M, et al : Psychotic Depression. Cambridge University Press, Cambridge, 2007 (上田諭, 他訳 : 精神病性うつ病-病態の見立てと治療. 星和書店, 東京, 2013).
 
18) Fink M, et al : Catatonia : A Clinician's Guide to Diagnosis and Treatment. Cambridge University Press, Cambridge, UK, 2003. (鈴木一正訳 : カタトニア-臨床医のための診断・治療ガイド. 星和書店, 東京, 2007).
 
P.144 掲載の参考文献
1) 日本うつ病学会治療ガイドライン II. うつ病 (DSM-5) /大うつ病性障害 2016. <http://www.secretariat.ne.jp/jsmd/mood_disorder/img/160731.pdf>
 
2) 浦田重治郎 : 心理教育を中心とした心理社会的援助プログラムガイドライン, 「統合失調症の治療およびリハビリテーションのガイドライン作成とその実証的研究成果報告書」2004.
 
3) 澤田法英 : 感情障害治療におけるShared Decision Makingの実際と判断能力. 臨精薬理 15 (11) : 1777-1784, 2012.
 
4) 安保寛明 : コンコーダンス患者の気持ちに寄り添うためのスキル 21. 医学書院, 東京, 2010.
 
5) 厚生労働省健康局 : 健康づくりのための睡眠指針 2014. <https://www.mhlw.go.jp/file/06-Seisakujouhou-10900000-Kenkoukyoku/0000047221,pdf>
 
6) 岩本邦弘 : 自動車運転を考慮した薬物療法の適正化. 臨精薬理 19 : 1419-1426, 2016.
 
7) こころのスキルアップ・トレーニング. <https://www.cbtjp.net/>
 
8) 田中輝明 : 双極性障害の評価尺度 : 過小診断と過剰診断の問題をふまえて. 臨精医 (3) : 251-259, 2011.
Medical*Online
9) 日本うつ病学会治療ガイドライン I. 双極性障害 2017. <http://www.secretariat.ne.jp/jsmd/mood_disorder/img/171130.pdf>
 
10) Colom F, et al : 双極性障害の心理教育マニュアル-患者に何を, どう伝えるか (秋山剛, 他監訳) 医学書院, 東京, 2012.
 
P.150 掲載の参考文献
1) 気分障害の治療ガイドライン作成委員会 : 日本うつ病学会治療ガイドライン II. うつ病 (DSM-5) /大うつ病性障害. 2016.
 
2) Rush A J, et al : Acute and longer-term out-comes in depressed outpatients requiring one or several treatment steps : a STAR*D report. Am J Psychiatry 163 : 1905-1917, 2006.
 
3) <http://www.pmda.go.jp/medical_devices/2017/M20170915001/58089000022900BZI00029_A100_1.pdf>
 
4) <https://www.jspn.or.jp/uploads/uploads/files/activity/Guidelines_for_appropriate_use_of_rTMS.pdf>
 
5) Horvath J C, et al : Transcranial magnetic stimulation : a historical evaluation and future prognosis of therapeutically relevant ethical concerns. J Med Ethics 37 : 137-143, 2011.
PubMed
6) Ridding M C, et al : Is there a future for therapeutic use of transcranial magnetic stimulation? Nat Rev Neurosci 8 : 559-567, 2007.
 
7) Rossi S, et al : Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol 120 : 2008-2039, 2009.
PubMed
8) Kito S, et al : Changes in regional cerebral blood flow after repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex in treatment-resistant depression. J Neuropsychiatry Clin Neurosci 20 : 74-80, 2008.
PubMed
9) Kito S, et al : Neuroanatomical correlates of therapeutic efficacy of low-frequency right prefrontal transcranial magnetic stimulation in treatment-resistant depression. Psychiatry Clin Neurosci 65 : 175-182, 2011.
PubMed
10) Fitzgerald P B, et al : An analysis of functional neuroimaging studies of dorsolateral prefrontal cortical activity in depression. Psychiatry Res 148 : 33-45, 2006.
PubMed
11) George M S, et al : Prefrontal cortex dysfunction in clinical depression. Depression 2 : 59-72, 1994.
 
12) Mayberg H S, et al : Reciprocal limbic-cortical function and negative mood : converging PET findings in depression and normal sadness. Am J Psychiatry 156 : 675-682, 1999.
PubMed
13) Lefaucheur J P, et al : Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clin Neurophysiol 125 : 2150-2206, 2014.
 
14) Schutter D J : Antidepressant efficacy of high-frequency transcranial magnetic stimulation over the left dorsolateral prefrontal cortex in double-blind sham-controlled designs : a meta-analysis. Psychol Med 39 : 65-75, 2009.
PubMed
15) Slotema C W, et al : Should we expand the toolbox of psychiatric treatment methods to include Repetitive Transcranial Magnetic Stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders. J Clin Psychiatry 71 : 873-884, 2010.
PubMed
16) Berlim M T, et al : Response, remission and drop-out rates following high-frequency repetitive transcranial magnetic stimulation (rTMS) for treating major depression : a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials. Psychol Med 44 : 225-239, 2014.
PubMed
17) Brunoni A R, et al : Repetitive transcranial magnetic stimulation for the acute treatment of major depressive episodes : a systematic review with network meta-analysis. JAMA Psychiatry 74 : 143-152, 2017.
PubMed
18) O'Reardon J P, et al : Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression : a multisite randomized controlled trial. Biol Psychiatry 62 : 1208-1216, 2007.
PubMed
19) George M S, et al : Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder : a sham-controlled randomized trial. Arch Gen Psychiatry 67 : 507-516, 2010.
PubMed
20) George M S, et al : The expanding evidence base for rTMS treatment of depression. Curr Opin Psychiatry 26 : 13-18, 2013.
PubMed
21) 鬼頭伸輔, 他 : 気分障害への反復経頭蓋磁気刺激 (rTMS). 機能脳神外 56 : 15-22, 2017.
Medical*Online
22) McGirr A, et al : Clinical efficacy and safety of repetitive transcranial magnetic stimulation in acute bipolar depression. World Psychiatry 15 : 85-86, 2016.
PubMed
23) Kito S, et al : A 6-month follow-up case study of low-frequency right prefrontal repetitive transcranial magnetic stimulation in treatment-resistant bipolar depression. J ECT 33 : e43-e44, 2017.
PubMed
P.161 掲載の参考文献
1) 五十嵐良雄 : 精神科クリニックにおけるビジネスマンのうつ病に対する復職支援. 臨精医 34 (7) : 983-985, 2005.
 
2) 樽味伸, 他 : うつ病の社会文化的試論-特に「ディスチミア親和型うつ病」について-. 日社精医誌 13 : 129-136, 2005.
 
3) 牛島定信, 他 : パーソナリティ障害とその周辺のリワーク. 精神医 55 (8) : 729-734, 2013.
 
4) 五十嵐良雄 : うつ病のリハビリテーション現場からみえる現代のうつ病. 臨精医 37 (9) : 1121-1123, 2008.
Medical*Online
5) Frank E, et al : Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch Gen Psychiatry 62 (9) : 996-1004, 2005.
PubMed
6) 五十嵐良雄 : 職場復帰から見た難治性うつ病とその治療上での工夫. 精神療法 36 (5) : 627-632, 2010.
 
7) 飯島優子, 他 : リワークプログラムにおけるチーム医療, 精神科医療のチーム医療実践マニュアル. pp58-76. 新興医学出版社, 東京, 2016.
 
8) 福田正人, 他 : 精神疾患におけるNIRSの意義. 精神疾患とNIRS, p40-51. 中山書店, 東京, 2009.
 
9) 五十嵐良雄 : リワークプログラムによる支援. 職場 X 双極性障害, p73-91. 南山堂, 2018.
 
10) Judd L L, et al : Major depressive disorder : A prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affective Disorder 50 : 97-108, 1998.
PubMed
11) 池田隆一, 他 : 会員施設を対象とした基礎調査における個人調査の7年間の集計. 第1回日本うつ病リワーク協会年次大会プログラム・抄録集, p112. 2018.
 
12) Kessler R C, et al : The Prevalence and Correlates of Adult ADHD in the United States : Results From the National Comorbidity Survey Replication. Am J Psychiatry 163 (4) : 716-723, 2006.
PubMed
13) Hofvander B, et al : Psychiatric and psychosocial problems in adults with normal-intelligence autism spectrum disorders. MBC psychiatry 9 : 35, 2009.
 
14) Lai M C, et al : Autism. Lancet 383 : 896-910, 2014.
PubMed
15) 五十嵐良雄他 : 障害者対策総合研究事業 (障害者政策総合研究事業 (精神障害分野) 「精神障害者の就労移行を促進するための研究」, 分担研究報告書「リワークプログラム利用者の復職後1年間の就労継続性に関する大規模調査」, p54-76, 2016. <https://mhlw-grants.niph.go.jp/niph/search/NIDD00.do?resrchNum=201616021A>
 
16) 佐渡充洋 : うつ病の社会的コスト. 治療 93 : 2467-2471, 2011.
Medical*Online
P.167 掲載の参考文献
1) Kitamura T : Psychiatric Initial Screening for Affective Disorders (PISA) (in Japanese). National Institute of Mental Health, National Center of Neurology and Psychiatry : Ichikawa 1992.
 
2) Furukawa T, et al : The Comprehensive Assessment List for Affective Disorders (COALA) : a polydiagnostic, comprehensive, and serial semistructured interview system for affective and related disorders. Acta Psychiatr Scand Suppl 387 : 1-36, 1995.
PubMed
3) Furukawa T A, et al : Time to recovery of an inception cohort with hitherto untreated unipolar major depressive episodes. Br J Psychiatry 177 : 331-335, 2000.
PubMed
4) Kanai T, et al : Time to recurrence after recovery from major depressive episodes and its predictors. Psychol Med 33 : 839-845, 2003.
PubMed
5) Furukawa T A, et al : How many well vs. unwell days can you expect over 10 years, once you become depressed? Acta Psychiatr Scand 119 : 290-297, 2009.
PubMed
P.174 掲載の参考文献
1) Greenberg P E, et al : The economic burden of depression in the United States : how did it change between 1990 and 2000? J Clin Psychiat 64 : 1465-1475, 2003.
 
2) Sobocki P, et al : Cost of depression in Europe. J Ment Health Policy Econ 9 : 87-98, 2006.
 
3) Sado M, et al : Cost of depression among adults in Japan in 2005. Psychiat Clin Neurosci 65 : 442-450, 2011.
 
4) Okumura Y, et al : Cost of depression among adults in Japan. Prim Care Companion CNS Disord 13 : 10m01082, 2011.
PubMed
5) Leal J, et al : Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 27 : 1610-1619, 2006,
PubMed
6) Knapp M : Hidden costs of mental illness. Brit J Psychiat 183 : 477-478, 2003.
PubMed
7) 大木洋子 : リワークプログラムの効果研究-国内研究のアウトカムと海外研究の動向-. 臨精医 41 : 1561-1571, 2012.
Medical*Online
8) 大木洋子 : メンタルクリニックにおけるリワークプログラムの治療構造とアウトカム. 精神医 55 : 761-767, 2013.
 
9) Simon G E, et al : Depression and work productivity : The comparative costs of treatment versus nontreatment. J Occup Environ Med 43 : 2-9, 2001.
PubMed
P.175 掲載の参考文献
1) 辻敬一郎, 他 : 臨精薬理 18 : 181, 2015.
 

第5章 診断・治療 ( 各論 )

P.184 掲載の参考文献
1) 高橋三郎, 他監訳 : 抑うつ障害群. DSM-5 精神疾患の診断・統計マニュアル 第1版, p155-186. 医学書院, 東京, 2014.
 
2) 高橋三郎監訳 : 双極性障害および関連障害群. DSM-5 精神疾患の診断・統計マニュアル 第1版, p123-154. 医学書院, 東京, 2014.
 
3) 井上令一監 : 小児と青年の抑うつ障害群と自殺. カプラン精神医学テキスト DSM-5 診断基準の臨床への展開 第3版, p1372-1383. メディカルサイエンスインターナショナル, 東京, 2016.
 
4) 井上令一監 : 早発性双極性障害. カプラン精神医学テキスト DSM-5 診断基準の臨床への展開 第3版, p1383-1392. メディカルサイエンスインターナショナル, 東京, 2016.
 
5) 日本うつ病学会監 : 児童思春期のうつ病. うつ病診療ガイドライン 第2版, p79-93. 医学書院, 東京, 2017,
 
6) 猪子香代 : うつ病性障害. 臨床児童青年精神ハンドブック (本城秀次, 他編), p268-274. 西村書店, 東京, 2016.
 
7) 鈴木太 : 双極性障害と重篤気分調節症臨床児童青年精神ハンドブック (本城秀次, 他編), p275-284. 西村書店, 東京, 2016.
 
P.191 掲載の参考文献
1) Ismail Z, et al : What characterizes late-life depression? Psychiatr Clin North Am 36 : 483-496, 2013.
PubMed
2) 三村將 : 老年期うつ病ハンドブック. 診断と治療社, 東京, 2009.
 
3) Chen P, et al : Update on the Epidemiology, Diagnosis, and Treatment of Mania in Older-Age Bipolar Disorder. Curr Psychiatry Rep 19 : 46, 2017.
 
4) Byers A L, et al : Depression and risk of developing dementia. Nat Rev Neurol 7 : 323-331, 2011.
PubMed
5) Hegeman J M, et al : Phenomenology of depression in older compared with younger adults : meta-analysis. Br J Psychiatry 200 : 275-281, 2012.
PubMed
6) Balsis S, et al : Comparing depression diagnostic symptoms across younger and older adults. Aging Ment Health 12 : 800-806, 2008.
PubMed
7) Reischies F M, et al : The symptom pattern variations of unipolar depression during life span : a cross-sectional study. Compr Psychiatry 31 : 457-464, 1990.
PubMed
8) World Health Organization. <http://www.who.int/2018>
 
9) 張賢, 他 : 【老年内科医に必要な精神神経疾患の知識】高齢者の自殺. 日老医会雑 49 : 547-554, 2012,
 
10) 楯林義孝 : 【高齢者のうつ病とその周辺】認知症とうつ病. 老精医誌 19 : 414-419, 2008.
 
11) Hyett M P, et al : Examining age effects on prototypic melancholic symptoms as a strategy for refining definition of melancholia. J Affect Disord 109 : 193-197, 2008.
PubMed
12) Marin R S : Differential diagnosis and classification of apathy. Am J Psychiatry 147 : 22-30, 1990.
PubMed
13) 馬場元 : 【精神医学症候群 (第2版) -発達障害・統合失調症・双極性障害・抑うつ障害-】抑うつ障害群 抑うつ症候群の病型 老年期の抑うつ症候群. 日臨別冊 : 540-545, 2017.
 
14) Lee S I, et al : Antidepressant apathy syndrome. Perspect Psychiatr Care 41 : 188-192, 2005.
PubMed
15) 馬場元 : 【双極性障害の薬物療法 : 病像や経過に応じて使い分けるコツ】高齢者の双極性障害. 臨精薬理 19 : 805-812, 2016.
 
16) Sajatovic M, et al : Aripiprazole therapy in 20 older adults with bipolar disorder : a 12-week, open-label trial. J Clin Psychiatry 69 : 41-46, 2008.
 
17) Sajatovic M, et al : Multisite, open-label, prospective trial of lamotrigine for geriatric bipolar depression : a preliminary report. Bipolar Disord 13 : 294-302, 2011.
PubMed
18) Forester B P, et al : Clinical Characteristics of Patients with Late Life Bipolar Disorder in the Community : Data from the NNDC Registry. Am J Geriatr Psychiatry 23 : 977-984, 2015.
PubMed
19) Young R C, et al : A Randomized Double-Blind Controlled Trial of Lithium and Divalproex in the Treatment of Mania in Older Patients With Bipolar Disorder. Am J Psychiatry 174 : 1086-1093, 2017.
PubMed
20) Sajatovic M, et al : Quetiapine for the treatment of bipolar mania in older adults. Bipolar Disord 10 : 662-671, 2008.
PubMed
21) Baruch Y, et al : Asenapine for elderly bipolar manic patients. J Affect Disord 145 : 130-132, 2013.
PubMed
22) 前嶋仁, 他 : 【うつ病】うつ病と認知症の関係. 最新医 71 : 1441-1446, 2016.
 
23) 前嶋仁, 他 : 【気分障害の治療ガイドライン新訂版】 (第6章) 身体疾患と抑うつ 認知症に伴う抑うつ 初期症状としての抑うつ. 精神科治療 27 : 229-234, 2012.
 
24) 三村將 : 前頭側頭葉変性症と紛らわしい病態 前頭側頭葉変性症と類似する精神疾患. 高次脳機能研 36 : 368-375, 2016.
 
25) Papazacharias A, et al : Bipolar Disorder and Frontotemporal Dementia : An Intriguing Association. J Alzheimers Dis 55 : 973-979, 2017.
PubMed
P.199 掲載の参考文献
1) Rush A J, et al : Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps : a STAR*D report. Am J Psychiatry 163 (11) : 1905-1917, 2006.
 
2) Thase M E, et al : When at first you don't succeed : sequential strategies for antidepressant nonresponders. J Clin Psychiatry 58 (Suppl 13) : 23-29, 1997.
 
3) American Psychiatric A. Practice guideline for the treatment of patients with major depressive disorder (3rd) 2010. <http://psychiatryonlineorg/guidelinesaspx>
 
4) Parker G B, et al : ldentifying "paradigm failures" contributing to treatment-resistant depression. J Affect Disord 87 (2-3) : 185-191, 2005.
 
5) Souery D, et al : Clinical factors associated with treatment resistance in major depressive disorder. results from a European multicenter study. J Clin Psychiatry 68 (7) : 1062-1070, 2007.
PubMed
6) 日本うつ病学会 : うつ病治療ガイドライン. 医学書院, 東京, 2017.
 
7) Kato M, et al : Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT. J Psychiatr Res 89 : 97-104, 2017.
PubMed
8) Kamijima K, et al : Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder : a randomized, double-blind placebo-controlled study (ADMIRE study). J Affect Disord 151 (3) : 899-905, 2013.
PubMed
9) LeBlanc A, et al : Shared Decision Making for Antidepressants in Primary Care : A Cluster Randomized Trial. JAMA Intern Med 175 (11) : 1761-1770, 2015.
PubMed
P.204 掲載の参考文献
1) Dunner D L, et al : Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 30 : 229-233, 1974.
PubMed
2) Maj M, et al : Reliability and validity of four alternative definitions of rapid-cycling bipolar disorder. Am J Psychiatry 156 : 1421-1424, 1999.
PubMed
3) 鈴木克治, 他 : ラピッドサイクラー. 気分障害 (上島国利, 他編), p441-448. 医学書院, 東京, 2008.
 
4) Geller B, et al : Prepubertal and early adolescent bipolarity differentiate from ADHD by manic symptoms, grandiose delusions, ultra-rapid or Ultradian cycling. J Affect Disord 51 : 81-91, 1998.
 
5) Riemann G, et al : The relationship between self-reported borderline personality features and prospective illness course in bipolar disorder. Int J Bipolar Disord 5 : 31, 2017.
PubMed
6) Schneck C D, et al : The prospective course of rapid-cycling bipolar disorder : Findings from STEP-BD. Am J Psychiatry 165 : 370-377, 2008.
PubMed
7) Carvalho A F, et al : Rapid cycling in bipolar disorder : a systematic review, J Clin Psychiatry 75 : e578-586, 2014.
PubMed
8) Valenti M, et al : Risk factors for rapid cycling in bipolar disorder. Bipolar Disord 17 : 549-559, 2015.
PubMed
9) Post R M, et al : Rapid cycling bipolar affective disorder : Lack of relation to hypothyroidism. Psychiat Res 72 : 1-7, 1997.
 
10) Kupka R W, et al : Rapid and non-rapid cycling bipolar disorder : a meta-analysis of clinical studies. J Clin Psychiatry 64 : 1483-1494, 2003.
PubMed
11) Oomen H A P C, et al : The prevalence of affective disorder and in particular of a rapid cycling of bipolar disorder in patients with abnormal thyroid function tests. Clin Endocrinol 45 : 215-223, 1996.
 
12) Wehr T A, et al : Rapid cycling in manic-depressives induced by tricyclic antidepressants. Arch Gen Psychiatry 36 : 555-559, 1979.
PubMed
13) El-Mallakh R S, et al : Antidepressants worsen rapid cycling course in bipolar depression : A STEP-BD randomized clinical trial. J Affect Disord 184 : 318-321, 2015,
PubMed
14) Koukopoulos A, et al : Course of the manic-depressive cycle and changes by treatments. Pharmakopsychiat 13 : 156-167, 1980.
 
15) Coryell W : Rapid cycling bipolar disorder : clinical characteristics and treatment options. CNS Drugs 19 : 557-569, 2005.
 
16) Lorenzo-Luaces L, et al : Rapid versus non-rapid cycling bipolar II depression : response to venlafaxine and lithium and hypomanic risk. Acta Psychiatr Scand 133 : 459-469, 2016.
PubMed
17) Yatham L N, et al : Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 20 : 97-170, 2018.
 
18) 日本うつ病学会気分障害の治療ガイドライン作成委員会 : 日本うつ病学会治療ガイドライン I. 双極性障害. 2017.
 
19) National Collaborating Centre for Mental Health (UK) : Bipolar Disorder : The NICE Guideline on the Assessment and Management of Bipolar Disorder in Adults, Children and Young People in Primary and Secondary Care. British Psychological Society, Leicester (UK), 2018.
 
20) Bauer M S, et al : Rapid cycling bipolar affective disorder. II. Treatment of refractory rapid cycling with high-dose levothyroxine : a preliminary study. Arch Gen Psychiatry 47 : 435-440, 1990.
PubMed
21) 鈴木克治, 他 : 治療抵抗性感情障害に対するサイロキシン (T4) の治療効果. 精神医 37 : 477-484, 1995.
 
22) Walshaw P D, et al : Adjunctive thyroid hormone treatment in rapid cycling bipolar disorder : A double-blind placebo-controlled trial of levothy-roxine (L-T4) and triiodothyronine (T3). Bipolar Disord 2018. [Epub ahead of print]
 
P.212 掲載の参考文献
1) Koukopoulos A, et al : Agitated depression as a mixed state and the problem of melancholia. Psychiatr Clin North Am 22 (3) : 547-564, 1999.
PubMed
2) American Psychiatric Association : Diagnostic and statistical manual of mental disorders, fourth edition, text revision. Washington DC, 2000.
PubMed
3) 武島稔 : 混合状態に対する薬物療法の選択肢-エビデンスと経験から-. 臨精薬理 19 (6) : 797-804, 2016.
 
4) American Psychiatric Association : Diagnostic and statistical manual of mental disorders. Arlington, VA, 2013.
 
5) Akiskal H S, et al : Gender, temperament, and the clinical picture in dysphoric mixed mania : Findings from a French national study (EPIMAN). J Affect Disord 50 (2-3) : 175-186, 1998.
 
6) Hantouche E G, et al : Clinical and psychometric characterization of depression in mixed mania : A report from the French national cohort of 1090 manic patients. J Affect Disord 96 (3) : 225-232, 2006.
 
7) Suppes T, et al : Mixed hypomania in 908 patients with bipolar disorder evaluated prospectively in the Stanley foundation bipolar treatment network : A sex-specific phenomenon. Arch Gen Psychiatry 62 (10) : 1089-1096, 2005.
PubMed
8) Benazzi F : Mixed depression : A clinical marker of bipolar-II disorder. Prog Neuropsychopharmacol Biol Psychiatry 29 (2) : 267-274, 2005.
PubMed
9) Takeshima M, et al : Impact of depressive mixed state in an emergency psychiatry setting : A marker of bipolar disorder and a possible risk factor for emergency hospitalization. J Affect Disord 111 (1) : 52-60, 2008.
 
10) Perugi G, et al : Mixed features in patients with a major depressive episode : The BRIDGE-II-MIX study. J Clin Psychiatry 76 (3) : e351-358, 2015.
 
11) Kim H, et al : More inclusive bipolar mixed depression definition by permitting overlapping and non-overlapping mood elevation symptoms. Acta Psychiatr Scand 134 (3) : 199-206, 2016.
PubMed
12) Fiedorowicz J G, et al : Subthreshold hypomanic symptoms in progression from unipolar major depression to bipolar disorder. Am J Psychiatry 168 (1) : 40-48, 2011.
PubMed
13) Goldberg J F, et al : Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms : Findings from the STEP-BD. Am J Psychiatry 164 (9) : 1348-1355, 2007.
PubMed
14) Takeshima M, et al : Association between the so-called "activation syndrome" and bipolar II disorder, a related disorder, and bipolar suggestive features in outpatients with depression. J Affect Disord 151 (1) : 196-202, 2013.
PubMed
15) Vieta E, et al : Mixed states in DSM-5 : Implications for clinical care, education, and research. J Affect Disord 148 (1) : 28-36, 2013.
 
16) Verdolini N, et al : Mixed states in bipolar and major depressive disorders : Systematic review and quality appraisal of guidelines. Acta Psychiatr Scand 2018 [Epub ahead of print].
 
17) Takeshima M : Treating mixed mania/hypomania : A review and synthesis of the evidence. CNS Spectr 22 (2) : 177-185, 2017.
PubMed
18) Stahl S M, et al : Guidelines for the recognition and management of mixed depression. CNS Spectr 22 (2) : 203-219, 2017.
PubMed
P.221 掲載の参考文献
1) Bertolote J M, et al : Suicide and psychiatric diagnosis : a worldwide perspective. World Psychiatry 1 : 181-185, 2002.
PubMed
2) American Psychiatric Association : Practice Guidelines for the Treatment of Psychiatric Disorders, Compendium 2004. American Psychiatric Association, Washington DC, 2004.
 
3) Nordentoft M, et al : Absolute risk of suicide after first hospital contact in mental disorder. Arch Gen Psychiatry 68 : 1058-1064, 2011.
PubMed
4) Brown G K, et al : Risk factors for suicide in psychiatric outpatients : a 20-year prospective study. J Consult Clin Psychol 68 : 371-377, 2000.
PubMed
5) Sokero T P, et al : Suicidal ideation and attempts among psychiatric patients with major depressive disorder. J Clin Psychiatry 64 : 1094-1100, 2003.
PubMed
6) Crescenzo F D, et al : Suicide Attempts in Juvenile Bipolar Versus Major Depressive Disorders : Systematic Review and Meta-Analysis. J Am Acad Child Adolesc Psychiatry 56 (10) : 825-831, 2017.
 
7) Valtonen H, et al : Suicidal ideation and attempts in bipolar I and II disorders. J Clin Psychiatry 66 : 1456-1462, 2007.
 
8) Isometsa E : Suicidal Behaviour in Mood Disorders-Who, When, and Why? Can J Psychiatry 59 (3) : 120-130, 2014.
PubMed
9) Janiri D, et al : Psychopathological characteristics and adverse childhood events are differentially associated with suicidal ideation and suicidal acts in mood disorders. Eur Psychiatry 53 : 31-36, 2018.
PubMed
10) Baldessarini R J, et al : Differential associations of affective temperaments and diagnosis of major affective disorders with suicidal behavior. J Affect Disord 210 : 19-21, 2017.
 
11) Hawton K, et al : Risk factors for suicide in individuals with depression : A systematic review. J Affect Disord 147 : 17-28, 2013.
PubMed
12) Vismara M, et al : Suicide attempts and clinical correlates in patients with bipolar I vs II disorder. Eur Psychiatry 52 : 113-115, 2018.
PubMed
13) Bobo W V, et al : The relative influence of individual risk factors for atternpted suicide in patients with bipolar I versus bipolar II disorder. J Affect Disord 225 : 489-494, 2018.
PubMed
14) Malhi G S, et al : Modeling suicide in bipolar disorders. Bipolar Disorders 20 : 334-348, 2018.
PubMed
15) Qin P, et al : Suicide risk in relation to psychiatric hospitalization : evidence based on longitudinal registers. Arch Gen Psychiatry 62 : 427-432, 2005.
PubMed
16) Holma K M, et al : Incidence and predictors of suicide attempts in DSM-IV major depressive disorder : a five year prospective study. Am J Psychiatry 167 : 801-808, 2010.
PubMed
17) Simon G E, et al : Risk of suicide attempt and suicide death in patients treated for bipolar disorder. Bipolar Disord 9 : 526-530, 2007.
PubMed
18) Stewart J G, et al : Adolescent self-injurers : Comparing non-ideators, suicide ideators, and suicide attempters. J Psychiatr Res 84 : 105-112, 2017.
PubMed
19) Zubrick S R, et al : The continuity and duration of depression and its relationship to nonsuicidal self-harm and suicidal ideation and behavior in adolescents 12-17. J Affect Disord 220 : 49-56, 2017.
PubMed
20) Hamza C A, et al : Examining the link between non suicidal self-inj ury and suicidal behavior : A review of the literature and an integrated model. Clin Psychol Rev 32 : 482-495, 2012.
 
21) Masi G, et al : Non suicidal self-injury in referred adolescents with mood disorders and its association with cyclothymic-hypersensitive temperament. J Affect Disord 227 : 477-482, 2018.
PubMed
22) Castellvi P, et al : Longitudinal association between self-injurious thoughts and behaviors and suicidal behavior in adolescents and young adults : A systematic review with meta-analysis. J Affect Disord 215 : 37-48, 2017.
 
23) Yerevanian B I, et al : Antidepressants and suicidal behaviour in unipolar depression. Acta Psychiatr Scand 110 : 452-458, 2004.
PubMed
24) Angst F, et al : Mortality of patients with mood disorders : follow-up over 34-38 years. J Affect Disord 68 : 167-181, 2002.
PubMed
25) Rihmer Z, et al : Do antidepressants threaten depressives? Toward a clinically judicious formulation of the antidepressant-suicidaiity FDA advisory in light of declining national suicide statistics from many countries. J Affect Disord 94 : 3-13, 2006.
 
26) Hammad T A, et al : Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 63 : 332-339, 2006.
PubMed
27) Simon G E, et al : Suicide risk during antide-pressant treatment. Am J Psychiatry 163 : 41-47, 2006.
 
28) Baldessarini R J, et al : Decreased risk of suicides and attempts during long-term lithium treatment : a meta-analytic review. Bipolar Disord 8 : 625-639, 2006.
PubMed
29) Ohgami H, et al : Lithium levels in drinkingwater and risk of suicide. Br J Psychiatry 194 : 464-465, 2009.
 
30) Rihmer Z, et al : Pharmacological prevention of suicide in patients with major mood disorders. Neurosci Biobehav Rev 37 : 2398-2403, 2013.
PubMed
31) Dunster-Page C, et al : The relationship between therapeutic aliance and patient's sUicidal thoughts, self-harming behaviours and suicide attempts : A systematic review. J Affect Disord 223 : 165-174, 2017.
 
32) Kawanishi C, et al : Assertive case management versus enhanced usual care for people with mental health problems who had attempted suicide and were admitted to hospital emergency departments in Japan (ACTION-J) : a multicentre, randomised controlled trial. Lancet Psychiatry 1 (3) : 193-201, 2014.
 
33) Furuno T, et al : Effectiveness of assertive case management on repeat self-harm in patients admitted for suicide attempt : Findings from ACTION-J study. J Affect Disord 225 : 460-465, 2018.
PubMed
P.229 掲載の参考文献
1) 厚生労働省ウェブサイトより : <http://www.mhlw.go.jp/kokoro/nation/iryou_keikaku.html>
 
2) 厚生労働省大臣官房統計情報部人口動態・保健社会統計課保健統計室 : 患者調査 上巻 (全国). 厚生労働省, 東京, 2015.
 
3) 酒井國男, 他 : 休職からの職場復帰体制の現実と課題-企業へのアンケート調査から-. 労働者健康福祉機構大阪産業保健推進センター報告書. 2006.
 
4) 伯井俊明, 他 : 精神障害による休職からの職場復帰体制の現実と課題～10年前との比較検討を含めて～. 労働者健康福祉機構大阪産業保健推進センター報告書. 2016.
 
5) 圓藤吟史, 他監 : 新改訂 病気をもちながらどこまで働けるか-疾病と就労の臨床判断-. 臨床病理刊行会, 東京, 2010.
 
6) 日本うつ病学会治療ガイドライン (II. うつ病 (DSM-5) /大うつ病性障害 2016) <http://www.secretariat.ne.jp/jsmd/mood_disorder/img/160731.pdf>
 
7) 厚生労働省 独立行政法人労働者健康福祉機構 : Relax職場における心の健康づくり～労働者の心の健康の保持増進のための指針～. 2012. <https://www.mhlw.go.jp/new-info/kobetu/roudou/gyousei/anzen/dl/101004-3.pdf>
 
8) 井上幸紀 : 産業現場に対し精神科主治医ができること, できないこと. 精神誌 118 (8) : 697-700, 2014.
 
9) 井上幸紀 : 精神科医療と職域の連携はなぜ必要か. 産業精保健 25 (4) : 322-324, 2017.
 
P.236 掲載の参考文献
1) 公益財団法人がん研究振興財団 : がんの統計 '17. 2018.
 
2) 内富庸介, 他編 : 精神腫瘍学. 医学書院, 東京, 2011.
 
3) Mitchell A J, et al : prevalence of depression, anxiety, and adjustment disorder in ontological, hematological, and palliative-care setting : a meta-analysis of 94 interview-based studies. Lancet Oncol 12 : 160-174, 2011.
 
4) Akechi T, et al : Major depression, adjustment disorders, and post-traumatic stress disorder in terminally ill cancer patients : associated and predictive factors. J Clinton Oncol 22 : 1957-1965, 2004.
 
5) Okamura H, et al : Psychological distress following first recurrence of disease in patients with breast cancer : prevalence and risk factors. Breast Cancer Res Treat 61 : 131-137, 2000.
PubMed
6) Uchitomi Y, et al : Depression and psychological distress in patientS during the year after curative resection of non-small-cell lung cancer. J Clinton Oncol 21 : 69-77, 2003.
 
7) Passik S D, et al : Oncologists' recognition of depression in their patients with cancer. J Clin Oncol 16 : 1594-1600, 1998.
 
8) Block S D : Assessing and managing depression in the terminally ill patient. ACP-ASIM End-of-life Care Consensus Panel. American College of Physicians-American Society of Internal Medicine. Ann Intern Med 132 : 209-218, 2000.
PubMed
9) Kugaya A, et al : Screening for psychological distress in Japanese cancer patients. Jpn J Clin Oncol 28 : 333-338, 1998.
PubMed
10) Akizuki N, et al : Development of the Impact Thermometer added to the distress Thermometer as a brief screening tool for adjustment disorders and/or major depression in patients with cancer. J Pain Symptom Manage 29 : 91-99, 2005.
 
11) Akizuki N, et al : Development of a brief screening interview for adjustment disorders and major depression in patients its cancer. Cancer 97 : 2605-2613, 2003.
PubMed
12) Andersen B L, et al : Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer : an American Society of Clinical Oncology guideline adaptadon. J Clin Oncol 32 : 1605-1619, 2014.
 
13) Akechi T, et al : Somatic symptoms for diagnosing major depression in cancer patients. Psychosomatic 44 : 244-248, 2003.
PubMed
14) McDaniel J S, et al : Assessment of depression and grief reactions in the medically ill. In : Psychiatric care of the medical patient (Stoudemire A, et al, eds). pp149-164. Oxford University Press, New York, 2000.
 
15) Kugaya A, et al : Prevalence, predective factors, and screening for psychologic distress in patients with newly diagnosed head and neck cancer. Cancer 88 : 817-823, 2000.
 
16) Akechi T, et al : Psychiatric disorders and associated and predictive factors in patients with unresectable nonsmall cell lung carcinoma-a longitudinal study. Cancer 15 : 2609-2622, 2001.
 
17) American Psychiatric Association : Diagnostic and Statistical Manual of Mental Disorder, Fourth Edition, Text Revision. American Psychiatric Association, Washington DC, 2000.
PubMed
18) Akechi T, et al : Psychotherapy for depression among incurable cancer patients. Cochrane Database Syst Rev Issue 2 : CD005537, 2008.
 
19) Okamura M, et al : Clinical experience of the use of a pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer. Psycho-Oncology 17 : 154-160, 2008.
PubMed
20) Kelly C M, et al : Selective serotonin reputable inhibitors and breast cancer mortality in women receiving tamoxifen : a population based cohort study. BMJ 340 : c693, 2010.
 
21) Donneyong M M, et al : Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors : multi-database cohort study. BMJ 354 : i5014-5018, 2016.
PubMed
22) Shimizu K, et al : Canpsychiatric intervention improve major depression in very near end-of-life cancer patients? Palliat Support Care 5 : 2-9, 2007.
 

第6章 ガイドライン

P.246 掲載の参考文献
1) 気分障害の治療ガイドライン作成委員会編 ; 日本うつ病学会監修 : うつ病治療ガイドライン 第2版. 医学書院, 東京, 2017.
 
2) 中村敏範, 他 : 「日本うつ病学会治療ガイドライン 2016年度版」を臨床で活用する. Prog Med 12 : 1375-1379, 2017.
Medical*Online
3) 小笠原一能, 他 : 気分障害治療ガイドラインupdateうつ病急性期治療ガイドラインについて-海外の比較と合わせて. 臨精薬理 20 : 495-504, 2017.
 
4) Kriston L, et al : Not as golden as standards shouid be : Interpretation of the Hamilton Rating Scale for Depression. J Affect Discord 128 : 175-177, 2011.
 
5) Zimmerman M, et al : Severity classification on the Hamilton Depression Rating Scale. J Affect Discord 150 : 384-388, 2013.
 
6) 日本うつ病学会抗うつ薬の適正使用に関する委員会. 「SSRI/SNRIを中心とした抗うつ薬適正使用に関する提言」<http://www.secretariat.ne.jp/jsmd/koutsu/pdf/antidepressant%20.pdf>
 
7) 厚生労働省 : 健康づくりのための睡眠指針 2014, 2014.
 
P.256 掲載の参考文献
1) 山田和男 : EBMと治療ガイドライン. 気分障害 (上島国利, 他編), p95-99. 医学書院, 東京, 2008.
 
2) American Psychiatric Association : Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 159 (suppl) : 1-50, 2002.
 
3) Grunze H, et al : The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders, part I : treatment of bipolar depression. World J Biol Psychiatry 3 (3) : 115-124, 2002.
PubMed
4) 日本うつ病学会 : 日本うつ病学会治療ガイドライン I. 双極性障害 2017. 2017. <http://www.secretariat.ne.jp/jsmd/mood_disorder/img/180125.pdf>
 
5) Goodwin G M, et al : Evidence-based guidelines for treating bipolar disorder : Revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol 30 (6) : 495-553, 2016.
PubMed
6) Fountoulakis K N, et al : The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017), part 2 : Review, grading of the evidence, and a precise algorithm. Int J Neuropsychopharmacol 20 (2) : 121-179, 2017.
 
7) Yatham L N, et al : Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 20 (2) : 97-170, 2018.
 

書評

最近チェックした商品履歴

Loading...